Forte Biosciences (FBRX) Cash & Equivalents (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Cash & Equivalents of $58.2 million for Q1 2026, up 26.92% year-over-year from $45.9 million in Q1 2025, and down 24.37% quarter-over-quarter from $77.0 million in Q4 2025.
Forte Biosciences (FBRX) Cash & Equivalents (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Cash & Equivalents for 11 consecutive years, with $58.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 26.92% year-over-year to $58.2 million; the TTM figure through Mar 2026 stood at $58.2 million (up 26.92% YoY), while the FY2025 annual figure was $77.0 million, up 245.97% from the prior year.
- Cash & Equivalents slipped to $58.2 million in Q1 2026 per FBRX's latest filing, from $77.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $106.1 million in Q2 2025 and bottomed at $16.4 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $45.7 million across 5 years, with a median of $40.0 million in 2022.
- Annual changes were most pronounced in 2024 — Cash & Equivalents sank 64.49% — and 2025, when it soared 469.51%.
- Forte Biosciences' Cash & Equivalents stood at $41.1 million in 2022, then slipped by 9.67% to $37.1 million in 2023, then plunged by 40.08% to $22.2 million in 2024, then soared by 245.97% to $77.0 million in 2025, then retreated by 24.37% to $58.2 million in 2026.
- Business Quant data shows FBRX's Cash & Equivalents at $58.2 million in Q1 2026, $77.0 million in Q4 2025, and $93.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 198.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 198.50 Mn |
| Mar 31, 2026 | 58.20 Mn |
| Dec 31, 2025 | 76.96 Mn |
| Sep 30, 2025 | 93.40 Mn |
| Jun 30, 2025 | 106.10 Mn |
| Mar 31, 2025 | 45.86 Mn |
| Dec 31, 2024 | 22.24 Mn |
| Sep 30, 2024 | 16.40 Mn |
| Jun 30, 2024 | 24.50 Mn |
| Mar 31, 2024 | 30.44 Mn |
| Dec 31, 2023 | 37.13 Mn |
| Sep 30, 2023 | 46.19 Mn |
| Jun 30, 2023 | 20.44 Mn |
| Mar 31, 2023 | 35.90 Mn |
| Dec 31, 2022 | 41.10 Mn |
| Sep 30, 2022 | 44.05 Mn |
| Jun 30, 2022 | 38.50 Mn |
| Mar 31, 2022 | 40.04 Mn |
| Dec 31, 2021 | 42.04 Mn |
| Sep 30, 2021 | 45.67 Mn |